Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Carboranylanilinoquinazoline EGFR-inhibitors: toward 'lead-to-candidate' stage in the drug-development pipeline.

Couto M, Alamón C, Sánchez C, Dávila B, Fernández M, Lecot N, Cabral P, Teixidor F, Viñas C, Cerecetto H.

Future Med Chem. 2019 Sep;11(17):2273-2285. doi: 10.4155/fmc-2019-0060.

PMID:
31581913
2.

Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment.

Couto M, García MF, Alamón C, Cabrera M, Cabral P, Merlino A, Teixidor F, Cerecetto H, Viñas C.

Chemistry. 2018 Mar 2;24(13):3122-3126. doi: 10.1002/chem.201705181. Epub 2017 Dec 22.

PMID:
29194843
3.

Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation.

Barth RF, Yang W, Coderre JA.

J Neurooncol. 2003 Mar-Apr;62(1-2):61-74. Review.

PMID:
12749703
4.
5.

Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma.

Futamura G, Kawabata S, Nonoguchi N, Hiramatsu R, Toho T, Tanaka H, Masunaga SI, Hattori Y, Kirihata M, Ono K, Kuroiwa T, Miyatake SI.

Radiat Oncol. 2017 Jan 23;12(1):26. doi: 10.1186/s13014-017-0765-4.

6.

High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.

Mondal MS, Gabriels J, McGinnis C, Magnifico M, Marsilje TH, Urban L, Collis A, Bojanic D, Biller SA, Frieauff W, Martus HJ, Suter W, Bentley P.

Toxicol Sci. 2010 Nov;118(1):71-85. doi: 10.1093/toxsci/kfq181. Epub 2010 Jul 14.

PMID:
20631060
7.

Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.

Ciaglia E, Abate M, Laezza C, Pisanti S, Vitale M, Seneca V, Torelli G, Franceschelli S, Catapano G, Gazzerro P, Bifulco M.

Int J Cancer. 2017 Feb 15;140(4):959-972. doi: 10.1002/ijc.30505. Epub 2016 Nov 16.

8.

Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine.

Barth RF, Yang W, Rotaru JH, Moeschberger ML, Boesel CP, Soloway AH, Joel DD, Nawrocky MM, Ono K, Goodman JH.

Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):209-18.

PMID:
10758326
9.

Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): application for photodynamic therapy and boron neutron capture therapy.

Hiramatsu R, Kawabata S, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake S, Kuroiwa T, Hao E, Vicente MG.

J Pharm Sci. 2015 Mar;104(3):962-70. doi: 10.1002/jps.24317. Epub 2014 Dec 26.

10.

[The history of the development and changes of quinolone antibacterial agents].

Takahashi H, Hayakawa I, Akimoto T.

Yakushigaku Zasshi. 2003;38(2):161-79. Japanese.

PMID:
15143768
11.

Small-Molecule Kinase-Inhibitors-Loaded Boron Cluster as Hybrid Agents for Glioma-Cell-Targeting Therapy.

Couto M, Mastandrea I, Cabrera M, Cabral P, Teixidor F, Cerecetto H, Viñas C.

Chemistry. 2017 Jul 12;23(39):9233-9238. doi: 10.1002/chem.201701965. Epub 2017 Jul 3.

PMID:
28605114
12.

Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.

Albanese C, Alzani R, Amboldi N, Degrassi A, Festuccia C, Fiorentini F, Gravina G, Mercurio C, Pastori W, Brasca M, Pesenti E, Galvani A, Ciomei M.

Br J Pharmacol. 2013 May;169(1):156-66. doi: 10.1111/bph.12112.

13.

A new boronated porphyrin (STA-BX909) for neutron capture therapy: an in vitro survival assay and in vivo tissue uptake study.

Matsumura A, Shibata Y, Yamamoto T, Yoshida F, Isobe T, Nakai K, Hayakawa Y, Kiriya M, Shimojo N, Ono K, Sakata I, Nakajima S, Okumura M, Nose T.

Cancer Lett. 1999 Jul 1;141(1-2):203-9. Erratum in: Cancer Lett 2000 Jul 31;155(2):209.

PMID:
10454263
14.

Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.

Li B, Chang CM, Yuan M, McKenna WG, Shu HK.

Cancer Res. 2003 Nov 1;63(21):7443-50.

15.

In vitro and in vivo evaluation of carboranyl uridines as boron delivery agents for neutron capture therapy.

Liu L, Barth RF, Tjarks W, Soloway AH, Anisuzzaman AK.

Anticancer Res. 1996 Jan-Feb;16(1):113-20.

PMID:
8615595
16.

Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption.

Yang W, Barth RF, Carpenter DE, Moeschberger ML, Goodman JH.

Neurosurgery. 1996 May;38(5):985-92.

PMID:
8727825
17.

EGF-receptor targeted liposomes with boronated acridine: growth inhibition of cultured glioma cells after neutron irradiation.

Kullberg EB, Wei Q, Capala J, Giusti V, Malmström PU, Gedda L.

Int J Radiat Biol. 2005 Aug;81(8):621-9.

PMID:
16298943
18.

Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors.

Sato H, Kuwashima N, Sakaida T, Hatano M, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Okada H.

Cancer Gene Ther. 2005 Sep;12(9):757-68.

PMID:
15832173
19.

Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy.

Zhang P, Hu L, Yin Q, Feng L, Li Y.

Mol Pharm. 2012 Jun 4;9(6):1590-8. doi: 10.1021/mp200600t. Epub 2012 Apr 30.

PMID:
22497485
20.

Boron neutron capture therapy for glioblastoma multiforme: enhanced drug delivery and antitumor effect following blood-brain barrier disruption induced by focused ultrasound.

Yang FY, Chen YW, Chou FI, Yen SH, Lin YL, Wong TT.

Future Oncol. 2012 Oct;8(10):1361-9. doi: 10.2217/fon.12.118.

PMID:
23130933

Supplemental Content

Support Center